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Chronic lymphocytic leukemia (CLL) is a malignancy
of CD5+ B cells that is characterized by the accumulation
of small, mature-appearing neoplastic lymphocytes in the
blood, marrow, and secondary lymphoid tissues. Genetic
factors contribute to the development of CLL. CLL is
more common in western countries relative to Asian
countries [1]. CLL can be divided into two main subsets.
These subsets are distinguished by express a mutated or
unmutated immunoglobulin heavy-chain variable region
gene (IGHV). Patients with unmutated IGHV CLL cells
typically havemore aggressive disease than patients with
CLL cells that express a mutated IGHV [2]. Several stud-
ies have disclosed numerous genetic alterations in CLL,
including chromosomal alterations, single-nucleotide
polymorphisms (SNPs) and alterations in noncoding
RNA [3,4]. The average incidence of CLL is different in
geographical regions and ranges from <0.01% in Asia
to 0.06% in Europe and the United States. The risk of
CLL is about two times higher for men than for women
and increases with age [5]. Genetic factors contribute to
CLL susceptibility. Patients with CLL have an 8.5-fold
increased risk of developing this disease, and the confor-
mity of CLL is higher among monozygotic twins than
among dizygotic twins. SNPs are associated with familial
CLL; they are the most common genetic variation in this
patients that contributes to heritable risk [6,7].
Reports have shown that exposure to Agent Orange is
an environmental risk factor for CLL. In addition, studies
suggest that exposure to insecticides might also be a
risk factor for this disease. Also, little evidence has195Polyphenols: Prevention and Treatment of Human Disease
https://doi.org/10.1016/B978-0-12-813008-7.00016-3demonstrated that ionizing radiation can increase the risk
of CLL. In addition, there is little evidence that viral infec-
tions are risk factors, and epidemiological studies have
not found evidence that blood transfusions can transmit
CLL. No studies showed that lifestyle and dietary factors
increase the risk of CLL [8].
Nearly 80% of cases with CLL convey at least one of
four common chromosomal alterations: a deletion in
chromosome del(13q), del(11q), del(17p) and trisomy
12. Del(13q) is themost common chromosomal alteration.
Within this deleted region is a part that controls the
expression of proteins that can inhibit apoptosis or that
are involved in cell cycle progression [9].
The landscape of CLL has undergone deep changes in
the recent years. CD20-targeting antibodies have
improved for conventional chemotherapy and have
shown a therapeutic outcome in the majority of CLL
patients. Due to the establishment of the critical role of
the B cell receptor signaling pathway in the pathogenesis
of CLL, several agents have been developed to target this
pathway. Lately, the observation of high expression
levels of the antiapoptotic mitochondrial protein Bcl-2
in CLL has led to the development of new compounds
that inhibit Bcl-2 and has shown high efficacy in CLL [10].
For over 40years, natural products have been used in
cancer therapy. The main sources of products with anti-
cancer activity are plants from the marine and terrestrial
environments. A major contribution comes from plants
such as alkaloids, taxoids, and podophyllotoxins. Due
to the rapid development of resistance to chemotherapeu-
tic drugs, the search for novel drugs is still a priority goal
for treatment of CLL. Moreover, the high toxicity usually© 2018 Elsevier Inc. All rights reserved.
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their undesirable side-effects increase the demand for
novel anticancer drugs active against untreatable cancer
such as CLL,with fewer side-effects andwith higher ther-
apeutic efficiency [11].2 CHRONIC LYMPHOCYTIC LEUKEMIA
Chronic lymphocytic leukemia (CLL) is a malignancy
of CD5+ B cells that is distinguished by the cumulating of
small, neoplastic lymphocytes in the blood, marrow, and
secondary lymphoid tissues, leading to lymphadenopa-
thy, leukemia cell infiltration of themarrow, lymphocyto-
sis, and splenomegaly. Previous studies showed that
genetic factors help in the development of CLL and it is
the most common adult leukemia in Western countries
compared with Asia. It is relatively rare in Korea and
Japan, even among Japanese people who migrate to
Western countries [1]. CLL is divided into two main sub-
types, which are difference in clinical behavior. These
subtypes are determined by whether CLL cells express
a mutated or unmutated immunoglobulin heavy chain
variable region gene (IGHV) [12]. CLL was estimated
to account for 19,000 new cases in the United States in
2016. The average incidence of CLL varies between indi-
viduals in different geographical regions. The risk of CLL
is about two-fold higher for men than for women and
increases with age [5]. Genetic factors help in disease sus-
ceptibility. Relatives of patients with CLL have an 8.5-
fold increased risk of developing this disease, and the
concordance of CLL is higher in monozygotic twins com-
pared with dizygotic twins. Genome-wide association
studies have confirmed single nucleotide polymorphisms
(SNPs) in nearly 30 loci that are related with familial CLL,
demonstrating that common genetic variation contrib-
utes to heritable risk. The altered expression of genes in
this location might contribute to disease development
[13]. Several studies have showed that exposure to Agent
Orange is a risk factor for CLL [14]. Moreover, evidence
suggests that exposure to insecticides might be a risk fac-
tor as well [15]. Also, little evidence shows that ionizing
radiation can increase the risk of CLL [16]. In addition,
there is little investigation that viral infections are risk fac-
tors, and studies have not found evidence that blood
transfusions can transmit CLL. No evidence suggests that
lifestyle factors or dietary factors increase the risk of
CLL [17].3 NOVEL TARGETS FOR CLL THERAPY
The clinical course of CLL is highly variable, but most
patients will eventually require treatment and indications
for treatment are related to the clinical stage. TreatmentIII. CANCER PREVENTION AND Toptions for the management of CLL have evolved signif-
icantly in the past decades. The initial chemotherapywith
chlorambucil has been replaced with targeted therapy
with the small-molecule inhibitor of Bruton’s tyrosine
kinase (BTK), ibrutinib and monoclonal antibodies
(mAbs) targeting CD20 (rituximab, obinutuzumab, and
ofatumumab). Current standards of care for patients with
relapsed or refractory CLL are ibrutinib, idelalisib alone
or with rituximab, and venetoclax alone or with rituxi-
mab [18]. The developments of the last few years have
been full of changes in an era of novel, molecularly tar-
geted therapies, made possible by extensive efforts to illu-
minate the biology of the disease that predated the new
targeted drugs. There is successful therapeutic targeting
of the B-cell, such as Bruton’s tyrosine kinase,
phosphatidylinositol-3-kinase, and B-cell lymphoma.
Moreover, new drugs targeted against CD37, myeloid
cell leukemia 1 (MCL-1), cyclin-dependent kinase 9
(CDK9), colony-stimulating factor 1R (CSF1R), etc., hold
promise for an even more robust therapeutic armamen-
tarium in the near future [18]. Another attractive strategy
for CLL therapy is to target proteins that control pro-
grammed cell death (apoptosis). Indeed, CLL is thought
to result from an imbalance between proliferation and
apoptosis. In addition, many factors are overexpressed
in CLL lymphocytes such as proteins of the BCL-2 and
IAP families. The BCL-2 family proteins control the mito-
chondrial outer membrane permeabilization (MOMP),
responsible for the activation of caspases [19].4 NATURAL COMPOUNDS FOR CLL
TREATMENT
The ancient medical literature reports that natural
products, especially plant products, have been used for
a long time. Natural products have a relevant role in
cancer therapy todaywith substantial numbers of antican-
cer agents used in the clinic. During the last fewyears, nat-
ural product–based drug discovery is increasing based on
new technologies, such as high-throughput screening and
combinatorial synthesis. Etoposide, paclitaxel, irinotecan,
and vincristine are famous examples of plant-derived
compounds; l-asparaginase, doxorubicin, bleomycin,
mitomycin C, and actinomycin D are drugs coming from
microbial sources, and citarabinewas a first drugoriginat-
ing from a marine source. All these agents are character-
ized by a variety of different mechanisms of action,
including inhibition of topoisomerases I or II, alkylation
of DNA, interference with tumor signal transduction,
and interaction with microtubules [20,21].
Many natural compounds have been used in the past
decades to treat several diseases due to their antidiabetic,
hepatoprotective, and cardioprotective activities [22].
Recently, the scientific research has focused on naturalREATMENT BY POLYPHENOLS
1974 NATURAL COMPOUNDS FOR CLL TREATMENTcompounds and their metabolites with preventive and
therapeutic activities, mainly phytochemicals such as ter-
penes, lignans, and polyphenolic compounds, as new
potential chemopreventive agents with apoptotic effects
on cancer, multidrug resistance reverting potential, or
cytotoxic activity [23]. Moreover, combination therapy,
that joins conventional chemotherapy with natural com-
pounds, is now considered a new promising strategy to
reduce cellular toxicity and overcome MDR, in particular
in CLL due to its development of leukemogenesis and
very complex origin [24]. In the following, we want to
update and summarize the recent applications of natural
compounds in the treatment of CLL.4.1 Curcumin
Curcumin (Fig. 16.1) has efficient chemosensitizing,
chemopreventive, chemotherapeutic, and antioxidant
activities [25,26]. The apoptosis of CLL B-lymphocytes
induced by curcumin is dose-dependent, and healthy
B lymphocytes are less sensitive to its cytotoxic effects
compared to CLL B-lymphocytes [27]. This compound
induces PARP cleavage in primary CLL B-lymphocytes
[2], that lead to the activation of programmed cell death
[28]. Interestingly, the authors did not show activation of
upstream caspases following curcumin exposure. In pri-
mary CLL B-lymphocytes obtained from CLL patients,
the mechanism of PARP cleavage remains unclear. The
release of cytochrome c from the mitochondrial mem-
brane is another cellular event that contributes to
curcumin-induced apoptosis [29].
In addition, curcumin also inhibits the constitutive
activation of prosurvival pathways, some of which are
preferentially active in primary CLL B-lymphocytes,
includingNF-κB, Akt, and STAT3 [30]. STAT3 plays a sig-
nificant role in the induction of angiogenic factors and
antiapoptotic genes, and is vital to various cytokine sig-
naling pathways [30]. Curcumin effectively inhibits con-
stitutive STAT3 phosphorylation in CLL B-lymphocytes
[30]. Mcl-1, a prosurvival gene downstream of STAT3,
is also down-regulated by curcumin in primary CLL
B-lymphocytes [31]. Constitutive phosphorylation of
Akt is down-regulated by curcumin in primary B-CLL
lymphocytes [32].
NF-κB transcription factor is a prosurvivalmolecule that
seems to be universally inhibited by curcumin. NF-κB is
down-regulated by curcumin in many different cancers.FIG. 16.1 Curcumin chemical structure.
III. CANCER PREVENTION AND TConstitutive phosphorylation of IκBα is inhibited by
curcumin in primary CLL B-lymphocytes, indicating that
genes downstream of NF-κB should be inhibited in these
cells. Following curcumin treatment, XIAP, a downstream
target of NF-kB, is down-regulated in primary CLL
B-lymphocytes [33], an interesting finding considering pre-
vious study demonstrating that Bcl-2 is a direct transcrip-
tional target of NF-κB and is down-regulated by
curcumin [32]. Treatment of CLL B-lymphocytes with
curcumin up-regulates BIM, a proapoptotic protein.Hence,
it can down-regulate survival pathways and up-regulate
apoptotic pathways in CLL B-lymphocytes [34].
There are several limitations to the anticancer activity
of curcumin, such as its poor absorption, poor pharmaco-
kinetics, low bioavailability, low water solubility, slow
cellular uptake, and rapid metabolism [35]. Bioavailabil-
ity of curcumin can be increased by liposomal encapsula-
tion and using nanoparticle formulations, increasing
membrane permeability through the incorporation of it
in micelles and phospholipids formulation, decreasing
hydrophobicity and chemical modifications [36]. Also,
the bioavailability of curcumin can also be attempted
through intravenous infusions. Moreover, quercetin
and prednisone can enhance the action of curcumin [34].4.2 Quercetin
Quercetin (3,30,40,5,7-penta-hydroxyflavone) (Fig. 16.2)
belongs to the wide group of natural anticancer com-
pounds proposed as apoptotic inducers in chemotherapy
or in adjuvant chemotherapy when associated with other
drugs. The role of quercetin as an anticancer agent has
been studied by several researchers. Gokbulut et al. dem-
onstrated that treatment of CLL B-lymphocytes with quer-
cetin and resveratrol caused dose-dependent inhibition of
cell proliferation and increased apoptotic cell population
through induction of caspase-3 activity. Cell cycle analysis
displayed cell cycle arrest mainly in G0/G1 for both poly-
phenols [37]. Russo and colleagues have shown that quer-
cetin significantly enhances anti-CD95- and rTRAIL-
induced cell death, increases caspase-3 and -9 activities,
and positivity to Annexin V. In addition, they proved that
association of quercetin with fludarabine increases the
apoptotic response in CLL B-lymphocytes of about two-
fold, compared with quercetin monotreatment [38].FIG. 16.2 Quercetin chemical structure.
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quercetin in association with ABT-737 synergistically
enhances apoptosis in CLL B-lymphocytes. They also
reported that the cellular uptake of quercetin is extremely
rapid, with an intracellular concentration of about
38.5ng/106 cells, after treatment with 25μM for 5min.
They demonstrated that the activity of protein kinase
CK2, which positively triggers PI3K/Akt pathway by
inactivating PTEN phosphatase, is inhibited by quercetin
immediately after its addition to CLL B-lymphocytes
(0–2min). PI3K activity was also inhibited by quercetin
within 60min from the treatment. The combined inhibi-
tion of CK2 and PI3K kinase activities by quercetin
restored ABT-737 sensitivity and increased lethality in
human leukemia cells [39].
Quercetin gallate tea-derived flavonol is also a multi-
target apoptosis inducer and proteasome inhibitor [40].
This compound can trigger both the intrinsic and extrin-
sic pathways in primary CLL B-lymphocytes, notably by
Mcl-1 down-regulation; the mechanism involves inhibi-
tion of the PI3K/AKT pathway, which in turn leads to
the instability of Mcl-1 mRNA and protein [38].4.3 Resveratrol
Resveratrol (Fig. 16.3) is a phytoalexin from the stilbene
family of polyphenols present in numerous fruits, plants,
andvineproducts. Resveratrolwas alreadyknown topro-
tect against cardiovascular problems. Studies have
revealed that this compound also displays potential anti-
cancer properties. The polyphenol compounds regulate
many different molecular targets and signaling pathways
such as ROS production, p53, AP-1, members of the IAP
and Bcl-2 families, proteasome activity, NF-kB, PI3K/
AKT, MAP kinase, TRAIL-death receptor, and mitochon-
drial pathways [41]. Resveratrol therefore displays a syn-
ergic effect in association with other agents for treatment
of CLL [37]. It is reported that resveratrol induces apopto-
sis in primary CLL B-lymphocytes, triggers themitochon-
drial pathway, and activates caspase-3 [42].4.4 Epigallocatechin Gallate
Epigallocatechin gallate (EGCG) (Fig. 16.4), the princi-
pal polyphenol in green tea, induces apoptosis in CLL
B-lymphocytes in vitro by caspase-3 activation and PARPFIG. 16.3 Resveratrol chemical structure.
III. CANCER PREVENTION AND Tcleavage and also through partial inhibition of VEGFR1
and VEGFR2 phosphorylation. Bcl-2 is down-regulated
by EGCG, as is Mcl-1 and XIAP [43]. Treatment of pri-
mary CLL B-lymphocytes with the combination of curcu-
min and EGCG was researched. EGCG has pleiotropic
effects. It can notably trigger caspase-dependent mito-
chondrial apoptosis in many tumor models, including
primary CLL B-lymphocytes in which it down-regulates
XIAP andMcl-1 [44]. Apoptotic pathways such as protea-
some inhibition are involved in EGCG’s mechanisms of
action. A Phase II study of EGCG in CLL has shown
promising results with reduction in lymphocytosis
and/or adenopathy in 29 out of 42 patients (69%) [45].4.5 Apigenin
Apigenin (Fig. 16.5) is a common dietary flavonoid
found in many vegetables, Chinese medicinal herbs, and
fruits and has multiple physiological functions, such as
antiviral, antibacterial, antioxidant, and strong antiin-
flammatory activities and blood pressure reduction [46].
Recently, apigenin has beenwidely researched for its anti-
tumor activities and low toxicity. Apigenin was observed
to suppress various human cancers in vitro and in vivo by
multiple biological effects, such as inducing cell cycle
arrest triggering, cell apoptosis and autophagy, invasion
and suppressing cell migration, and stimulating an
immune response. There are several signaling pathways
modulated by apigenin, including the PI3K/AKT,
MAPK/ERK, JAK/STAT, NF-κB and Wnt/β-catenin
pathways [47]. Apigenin has proapoptotic activity in
B-CLL lymphocytes, and this effect has been associated
with inhibition of the PI3K/AKT pathway and decreased
AKT phosphorylation. Also, apigenin is known to inhibitFIG. 16.5 Apigenin chemical structure.
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1994 NATURAL COMPOUNDS FOR CLL TREATMENTbothproteasomeandCDKactivities [40] and to target sev-
eral apoptotic pathways; the compound may act through
several mechanisms in CLL B-lymphocytes [48].4.6 Ellagic Acid
Ellagic acid (EA) (Fig. 16.6) is a natural phenolic con-
stituent that is contained in ellagitannins in grapes, straw-
berries, nuts, raspberries, black currents, pomegranates,
green tea, and the bark and stem of Eucalyptus maculata,
Eucalyptus globulus, and nuts. Recent in vitro and in vivo
experiments have revealed that EA elicits anticarcino-
genic effects by inhibiting tumor cell proliferation, break-
ing DNA binding to carcinogens, blocking virus
infection, disturbing inflammation, inducing apoptosis
and angiogenesis, and drug-resistance processes required
for tumor growth and metastasis [49,50]. Based on our
study EA decreases the percentage of viable cells andFIG. 16.7 The mechanism of action of ellagic acid described by Salimi
III. CANCER PREVENTION AND Tinduced apoptosis also increased ROS formation, mito-
chondria swelling, MMP decrease, and cytochrome c
release in mitochondria isolated from CLL
B-lymphocytes (Fig. 16.7). Our results suggest that EA
can act as an anticancer candidate by directly and selec-
tively targeting mitochondria that could induce apopto-
sis through the mitochondria pathway with increasing
ROS production, which finally ends in cytochrome c
release, caspase 3 activation, and apoptosis in cancerous
B-lymphocytes isolated from CLL patients [51].4.7 Acacetin
Natural agents are employed in cancer chemopreven-
tion to reverse, suppress, or prevent cancer progression.
Acacetin (5,7-dihydroxy-40-methoxyflavone) (Fig. 16.8)
exerts antiplasmodial, antimutagenic, antiinflammatory,
antiperoxidant, and anticancer effects by suppressing
the migration and invasion of human cancer cells. Acace-
tin has also been shown to exert an antiproliferative effect
by blocking cell cycle progression and inducing apoptosis
[52]. Salimi et al. have found that acacetin (10μM) can
selectively induce apoptosis on CLL B-lymphocyte
(25% at 24h) by directly targeting mitochondria, through
increased reactive oxygen species (ROS) formation, MMP
collapse, MPT, release of cytochrome c, caspase 3 activa-
tion, and finally apoptosis, while sparing normal healthy
B-lymphocytes unaffected at similar concentrationset al. on CLL B-lymphocytes [51] .
REATMENT BY POLYPHENOLS
FIG. 16.8 Acacetin chemical structure.
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showed a potent in vivo anticancer activity in CLL xeno-
graft mouse models. These findings indicate that acacetin
accumulates and kills CLL B-lymphocyte in a rather
selective way through targeting cancerous mitochondria
and ROS formation, which ends in CLL therapy [53].4.8 Chrysin
Chrysin (5,7-dihydroxy-2-phenyl-4H-chromen-4-one)
(Fig. 16.10) is a natural flavonoid. Chrysin has been
recently shown to be a potent inhibitor of aromatase
and of human immunodeficiency virus activation in
models of latent infection. It has also demonstrated anti-
oxidant and antiinflammatory effects, and has shown
cancer chemopreventive activity via induction of apopto-
sis in a diverse range of human and rat cell types. In most
of the cancer cells, chrysin has been shown to induce apo-
ptosis and inhibit proliferation, and is more potent than
other tested flavonoids in leukemia cells, where chrysin
is likely to act via activation of caspases and inactivation
of Akt signaling in the cells. Moreover, structure-activity
relationships have revealed that the chemical structure of
chrysin meets the key structural requirements ofFIG. 16.9 The mechanism of action of acacetin described by Salimi et a
III. CANCER PREVENTION AND Tflavonoids for potent cytotoxicity in leukemia cells [54].
Zaric and colleagues demonstrated that exposure of
MOLT-4, JVM-13 cell lines and B-CLL cells to the concen-
tration of chrysin of 10μM and higher selectively
decreased viability of cells in this cell population, but
not in the PBMC derived from healthy subjects; LC50
values of chrysin for B-CLL cells were 51μM for 24h
and 32μM for 48h of incubation, respectively. These find-
ings demonstrated that chrysin induces the activation of
proapoptotic Bax and decreases the expression of antia-
poptotic Bcl-2 protein, releases cytochrome c from the
mitochondria into cytosol, and cleavages/activates
caspase-3, subsequently leading to the activation of apo-
ptosis of B-CLL cells [55]. Also, Salimi et al. investigated
the effect of chrysin on isolated normal and CLL
B-lymphocytes and their isolated mitochondria. They
reported a selective and significant increase in cytotoxic-
ity, intracellular reactive oxygen species, mitochondrial
membrane potential collapse, ADP/ATP ratio, caspase
3 activation, and finally apoptosis in chrysin-treated
CLL B-lymphocytes. Moreover, they determined that
chrysin selectively inhibits complex II and ATPases in
cancerous mitochondria [56].4.9 Wogonin
Wogonin (5,7-dihydroxy-8-methoxy-2-phenyl-4H--
chromen-4-one) (Fig. 16.11) is a traditional Chinese herb
obtained from Scutellaria baicalinase’s Georgi that has been
widely researched and used for inflammatory and aller-
gic diseases with its medication effects of potential
removing toxins and cleansing heat. Studies have shown
inhibitory effects of wogonin on a number of differentl. on CLL B-lymphocytes [53].
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FIG. 16.10 Chrysin chemical structure.
FIG. 16.11 Wogonin chemical structure.
201REFERENCEScancer cells. The mechanisms of action are modulation of
the p53 signaling pathway, G1 phase arrest, antitumor
angiogenesis by inhibition of VEGF, and apoptosis
through the mitochondrial pathway. These works indi-
cate that wogonin is a new anticancer agent with
enhancement of the curative effect on chemo-insensitive
tumors that may clinically benefit ovarian cancer patients
[57]. Polier et al. demonstrate for the first time that wogo-
nin and structurally related natural flavones, for example
apigenin, chrysin, and luteolin, are inhibitors of cyclin-
dependent kinase 9 (CDK9) and block phosphorylation
of the carboxy-terminal domain of RNA polymerase II.
This effect leads to reduced RNA synthesis and subse-
quently rapid down-regulation of the short-lived antia-
poptotic protein myeloid cell leukemia 1 (Mcl-1)
resulting in apoptosis induction in cancer cells. They
showed that genetic inhibition of Mcl-1 or CDK9 expres-
sion by siRNA is sufficient tomimic flavone-induced apo-
ptosis. Pull-down and in silico docking studies
demonstrate that wogonin directly binds to CDK9, pre-
sumably to the ATP-binding pocket [58]. D€urr et al.
showed in CLL cocultures that wogonin treatment results
in a concentration-dependent apoptosis induction, which
is significantly increased by the addition of TNFα. Also,
they proved that wogonin significantly reduces spleen
weights and leads to a reduced CLL content in the spleen,
the bone marrow, and the peritoneal cavity. If treatment
is started in the advanced disease stage, wogonin slightly
lowered spleen weight and the CLL content in the spleen,
whereas the percentage of CLL B-lymphocytes in the
peripheral blood was increased. Interestingly, in their
work wogonin treatment results in a loss of cell surface
TNFR1 expression in splenic CLL B-lymphocytes and
increased TNFR1 levels in the serum. These data suggest
that wogonin induces a redistribution of CLL
B-lymphocytes in vivo, preventing their homing to lym-
phoid organs and that loss of TNFR1 expression might be
involved in this process [59].III. CANCER PREVENTION AND T5 CONCLUSIONS
With a rising number of new cases of CLL, novel
agents that could cure or prevent cancers are still very
much needed. Most anticancer agents act by induction
of apoptosis and cell cycle arrest, as well as through an
inhibition and proliferation of cell growth. This chapter
indicates that many of the natural products have
been shown to have antileukemic activities in CLL
B-lymphocytes and that they exert their effects through
one of the aforementioned mechanisms. It is expected
that the effects of these compounds on cell cycle, cell
growth, and proliferation, as well as induction of apopto-
sis in CLL B-lymphocytes, will provide clues for the pre-
diction of novel agents that may be useful in cancer
chemoprevention or chemotherapy. Also, the combina-
tion of some natural compounds enhances the antileuke-
mic activity of some agents, while other reports indicate
that such combinations are not always beneficial in terms
of potentiating the action of other antileukemic agents.
In addition, the chapter highlights some natural products
obtained from plants and fruits that are used as
medicines against CLL. Studies suggested that these
agents show a good potential for combating CLL
B-lymphocytes. These herbs and fruits could be the best
candidates for future CLL therapy, with better acceptabil-
ity as compared to chemotherapy, easier availability, and
minimal adverse effects; it is also likely they will provide
more potent antileukemic agents in future.References
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